Sudarshan Pharma Boosts Manufacturing Capacity with Rs.25.5 Crore Investment in Operational API Facility

Sudarshan Pharma Industries Limited (SPIL) is making a strategic capex investment of Rs.25,50,00,000/- for the transfer of capital assets from Srigen Lifesciences, an API Manufacturing company. This investment will significantly increase SPIL’s manufacturing capacity, accelerate its growth in the API and specialty chemicals sectors, and strengthen its position in domestic and global markets. The acquired facility will be used for the production of high-value, technically complex pharmaceutical ingredients, offering an expanded product portfolio, faster time-to-market, and regulatory advantages.